Articles tagged with Pancreatic Cancer
In a mouse model of unresectable pancreatic cancer, administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival. The study found that FG-4592 effectively mimicked hypoxia in normal tissues, protecting them from radiation damage.
Researchers found that the interaction between pancreatic stellate cells and cancer cells could be exploited due to high levels of LIF, a key protein responsible for activating PSCs in cancer cells. Elevated LIF levels correlate with disease progression and chemotherapy resistance.
Researchers at Salk Institute uncover role of signaling protein LIF in pancreatic cancer development and progression, suggesting it may be a useful biomarker for earlier diagnosis and more effective therapies. Elevated LIF levels were significantly correlated with tumor cell status and response to chemotherapy.
A new diagnostic method for pancreatic cancer has been developed by researchers at the University of Copenhagen, utilizing circular DNA to identify cancer cells in blood tests. The technology is expected to classify cancer cells in individual patients and implement personalized treatment regimens, leading to increased survival rates.
Researchers from CNIO have successfully removed advanced pancreatic ductal adenocarcinoma (PDA) in animal models through combined inhibition of EGFR and c-RAF kinase. This breakthrough has shown significant promise for developing new cancer treatments.
Researchers have identified a key hormone receptor called RORγ that promotes tumor growth and is responsible for therapy resistance in pancreatic cancer. Blocking this receptor slows patient-derived tumor growth and improves survival in animal models, providing new avenues for research and potential therapies.
Researchers found that rucaparib reduced tumor size and controlled growth in 17 out of 19 patients with BRCA1, BRCA2, or PALB2 mutations. The study provides promising early evidence for this approach as a less toxic option.
A subgroup of patients with advanced BRCA- or PALB2-mutated pancreatic cancer showed sustained clinical responses to rucaparib, a PARP inhibitor. The treatment provided complete or partial responses and reduced tumor size in some instances.
A Mayo Clinic study found that extended chemotherapy, a normal CA 19-9 tumor marker, and a dead tumor after surgery can significantly increase survival time for patients with advanced pancreatic cancer. The study achieved an average survival time of 58.8 months, or nearly five years.
A study found that excess body weight before age 50 is strongly associated with an increased risk of dying from pancreatic cancer. The research, which analyzed data from over 963,000 adults, suggests that excess weight measured earlier in adulthood may be more closely linked to pancreatic cancer risk than previously thought.
A new combination of immunotherapy and chemotherapy has caused tumors to shrink in 83% of patients with metastatic pancreatic cancer. The treatment, involving a CD40 antibody, checkpoint inhibitor, and standard-of-care chemotherapy, showed manageable side effects, suggesting a durable response.
The Pancreatic Cancer Collective has awarded two million-dollar grants to AI teams developing tools to identify high-risk individuals with pancreatic cancer. One team will focus on rare gene variants and the other on machine learning analysis of clinical records and images.
African American women with poor oral health may face a substantially increased risk of developing pancreatic cancer. Researchers found that adult tooth loss and periodontal disease prevalence were associated with a higher risk, particularly among those who had lost at least five teeth.
A study published in Nature identified a new approach to starve pancreatic cancer cells of molecular resources. The researchers found that the protein syndecan-1 plays a critical role in regulating macropinocytosis, a mechanism used by cancer cells to scavenge resources and divide.
Research highlights the development of next-generation CAR T-cells and immune profiling to overcome tumor resistance. SU2C presents work on cancer interception, convergence, and clinical trials for pancreatic, pediatric, brain, colorectal, lung, ovarian, and breast cancers.
Researchers established two human pancreatic cancer cell sublines with high metastasis potential, MIA PaCa-2 In8 and Panc-1 In8, which demonstrated increased migration, invasion, and clonogenic abilities compared to their parental cells. The study also identified a dysregulated lncRNA-miRNA-mRNA competitive endogenous RNAs (ceRNAs) net...
Researchers found that tumor-associated macrophages release compounds that block the action of gemcitabine in malignant cells. The study suggests that patients with fewer macrophages in their tumors may respond better to chemotherapy. This discovery could lead to new approaches for treatment.
A recent study found that high levels of the 'proofreading' enzyme PHLPP1 lead to low PKC levels in pancreatic cancer patients, associated with poor prognosis. The researchers aim to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC to improve survival rates.
Researchers have identified a promising new therapeutic strategy using two types of drug inhibitors to treat pancreatic cancer. The approach combines chloroquine with an inhibitor of the replication stress response pathway, showing potential in reducing tumor growth and improving prognosis.
Researchers at GW Cancer Center discovered USP15 as a potential biomarker for treatments of breast and pancreatic cancers. The enzyme regulates homologous recombination repair and cancer cell response to PARP inhibitors.
Researchers found that oral bacteria are associated with the severity of cystic pancreatic tumours, which can become cancerous. The study suggests that certain oral bacteria may play a role in the development of pancreatic cancer.
Researchers at Huntsman Cancer Institute discovered a combination drug therapy that may effectively combat the disease. The study, led by Conan Kinsey and Martin McMahon, found a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer.
Researchers have discovered a combination drug therapy that may effectively combat pancreatic cancer. The Pancreatic Cancer Collective, led by Martin McMahon and David Tuveson, has received funding to support clinical trials of the new treatment.
Researchers at UPMC and the University of Pittsburgh School of Medicine discovered genetic flags in 17% of tumors indicating susceptibility to existing chemotherapy drugs. The study's findings could lead to personalized treatment approaches for pancreatic cancer patients, increasing survival rates.
Researchers at UNC Lineberger Comprehensive Cancer Center have made a promising discovery in treating pancreatic cancer by making cells reliant on autophagy, a process of cellular recycling. A novel treatment strategy combining an autophagy inhibitor with another compound has shown increased efficacy in laboratory studies.
A retrospective study found that inherited mutations in pancreatic cancer susceptibility genes may increase the risk of developing pancreatic cancer in patients with specific precursor lesions. The study analyzed DNA from 315 patients and found a higher likelihood of invasive pancreatic cancer in those with inherited mutations.
Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2. Alteration in transcription and enhancer landscape occurs during disease progression, offering a potent therapeutic mark for targeting cancer cells.
Researchers identified a gene called UCP-1 that may predict the development of pancreatic cancer in people with Type 2 diabetes. The study found three distinct metabolic phases prior to diagnosis, characterized by rising blood glucose levels and changes in body fat.
Researchers have identified at least four different types of scar tissue in human pancreatic cancer, each influencing the disease in a unique way. This discovery may lead to tailor-made treatments, including immunotherapies, that target the powerful scar tissue wall protecting the cancer.
Cancer rates linked to obesity are rising faster in US young adults compared to older generations. Incidence of certain cancer types such as colorectal, uterine corpus, and pancreatic cancer has increased significantly in younger age groups.
A new 3D imaging technique has revealed that pancreatic cancers can develop in two distinct types - 'endophytic' and 'exophytic' - depending on the size of the duct. This breakthrough may lead to improved treatments for pancreatic cancers by better understanding how cancer grows.
Researchers found distinct bacteria on the tongue of early-stage pancreatic cancer patients compared to healthy individuals. The study suggests a potential link between the immune system and pancreatic cancer, paving the way for new diagnostic or preventive tools.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
A new recovery pathway has been implemented to reduce hospital stays after the Whipple operation by 15 days, allowing patients with pancreatic cancer to transition more quickly to the next phase of treatment. The study found that this accelerated care did not increase complication rates and improved patient outcomes.
A new combination blood test has been developed to detect pancreatic cancer earlier, with a detection rate of nearly 70% and a false-positive rate of less than 5%. The test uses two different sugars produced by pancreatic cancer cells and can detect subtypes that may have been missed by existing tests.
Researchers identified VISTA on immune cells infiltrating pancreatic tumors, which resisted immune checkpoint blockade drugs. The study highlights the importance of stroma and found higher expression of VISTA in pancreatic tumors compared to melanoma.
The US cancer death rate has declined by 27% since 1991, primarily due to reductions in smoking and advances in early detection and treatment. Despite this progress, socioeconomic inequalities have widened, with poorer counties experiencing a disproportionate burden of preventable cancers.
Researchers discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, indicating a possible pathway for treatment. The approach has promise for patients who are or become resistant to immunotherapy drugs after a recurrence of their tumors.
A phase I/II trial found that combining nab-paclitaxel with gemcitabine significantly improved survival rates even among patients with reduced health status. The study's results suggest alternative treatment options for patients typically underrepresented in clinical trials.
The Pancreatic Cancer Collective has awarded $7 million in grants to seven teams of top cancer researchers. The funding will support clinical studies and accelerate the translation of research findings into treatments, with the goal of improving patient outcomes for pancreatic cancer.
A team of UC San Diego researchers has received a $1 million Stand Up To Cancer grant to test drugs that block signals driving pancreatic cancer growth. The study aims to identify new therapies that can more effectively block tumor growth and metastasis.
Researchers have discovered a new compound, ancistrolikokine E3, from a Congolese rainforest vine that effectively targets and kills pancreatic cancer cells. The compound inhibits the Akt/mTOR pathway and autophagy pathway, leading to dramatic changes in cell morphology and preventing metastasis formation.
Researchers have identified a compound, ancistrolikokine E3, from the twigs of the Ancistrocladus likoko vine that kills pancreatic cancer cells when nutrients are scarce. The compound inhibits the Akt/mTOR pathway, which is responsible for the aggressive proliferation of these cancer cells.
Researchers identified TP63 as the culprit behind aggressive pancreatic cancer's addictive behavior. Suppressing its activity could lead to a tumor's demise. The study aims to understand why TP63 gets active in some patients' pancreas, with the goal of developing a treatment to improve their survival.
Research has found a strong link between adolescent weight and an increased risk of pancreatic cancer later in life. The study analyzed data from over 1.7 million Israeli adolescents and found that obesity was associated with a four-fold higher risk of pancreatic cancer, even among those who were not obese.
Researchers are investigating the link between blood clots and pancreatic tumors, which could lead to more effective treatments for patients with pancreatic cancer. The study aims to understand how blood clots form and contribute to tumor growth, potentially leading to new therapeutic approaches.
Researchers developed an antibody to block DKK3, which stimulated cancer growth and resistance to therapy. In a mouse study, the treatment significantly prolonged life and boosted immune cell infiltration.
Researchers found that patients with a non-functional IDO2 gene had more favorable outcomes when receiving radiotherapy, living cancer-free for almost twice as long. The discovery could lead to personalized treatment recommendations and improve patient survival rates.
Researchers at UNIGE and HUG discovered that mucinous tumours of the ovary and pancreas originate from embryonic germ cells that migrate to reproductive organs. These cells can mistakenly stop in other organs, leading to cancer decades later.
A new cell-based immunotherapy using 'educated killer cells' has shown promise in eradicating pancreatic cancer, including cases where tumours have spread to multiple organs. The treatment could potentially be administered to human patients without toxic side effects.
A study found that female-specific genetic mutation ATRX increases susceptibility to pancreatitis and pancreatic cancer. The research team discovered that deleting the gene in females led to increased progression to cancer, while males with the mutation experienced reduced risk of injury and progression to cancer.
A large observational study found that individuals with diabetes are at a higher risk of developing certain cancers, including colorectal and breast cancer. The study also showed that people with diabetes who are diagnosed with cancer have poorer survival rates compared to those without diabetes.
A new drug called Metavert has shown promising results in blocking pancreatic cancer growth in laboratory mice. The study also found that Metavert may prevent patients from developing resistance to currently used chemotherapies.
A study of 50,000 people found that over 80% of those with identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer are unaware they carry the gene. The findings highlight the need for effective DNA-based screening to identify high-risk individuals before a cancer diagnosis.
Researchers have developed a new blood test that can detect pancreatic cancer in its earliest stages with 96% accuracy, providing a potential breakthrough for earlier diagnosis and treatment. The test uses an antibody microarray to identify specific immune-regulatory proteins and cancer-associated antigens.
The new study reveals that different KRAS mutations have distinct effects on the KRAS protein's molecular-level function. The findings enhance understanding of cancer-causing mutations and may lead to the development of targeted drug therapies.
Researchers at University of Houston develop synthetic compound that inhibits two major pathways of pancreatic cancer. The drug, MA242, targets NFAT1 and MDM2, reducing tumor growth and progression.
The foundation grants four-year, $231,000 fellowships to support novel projects and encourage early career researchers in cancer science. The recipients are working on innovative projects such as developing T-cell receptors for immunotherapy and understanding protein modification in cancer development.
Researchers at the GW Cancer Center will develop a model to study the COMPASS complex in pancreatic cancer and possible targeted therapies. The goal is to identify molecular vulnerabilities and treat patients based on their likelihood to respond to tailored treatments.
A new study found that Cannabidiol (CBD) significantly improved the survival rate of mice with pancreatic cancer when used alongside chemotherapy. The treatment resulted in nearly tripled survival time compared to those receiving chemotherapy alone.